Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Photobiomodulation therapy: a promising treatment for insulin resistance in type 2 diabetes.

Zafari J., Sadeghi H., Abbasinia H., Najjar N., Jamali S., Javani Jouni F.

Animal Study on Type 2 Diabetes, published in In Vitro Cell Dev Biol Anim (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
In Vitro Cell Dev Biol Anim (2025)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
40437150
DOI
10.1007/s11626-025-01051-0

Abstract (original English)

Type 2 diabetes mellitus (T2DM) affects over 90% of diabetic patients and is characterized by insulin resistance (IR), primarily due to impaired GLUT4 function and abnormalities in insulin signaling within adipose and skeletal muscle cells. Dysfunctional adipose tissue elevates triglyceride and fatty acid levels, worsening IR. Photobiomodulation therapy (PBMT), which employs low-power light, has emerged as a potential treatment by enhancing glucose metabolism and reducing inflammation through the activation of the PI3K/AKT signaling pathway. Key factors influencing IR include FOXO1, GFAT-2, and PTP1B, which play significant roles in insulin signaling and glucose homeostasis. In this study, 3T3-L1 preadipocytes were cultured in high glucose DMEM with FBS and antibiotics, with differentiation induced using dexamethasone and insulin, followed by laser treatment. The viability of preadipocytes and adipocytes was assessed using the MTT assay, while oil red O staining quantified lipid droplet formation. An insulin resistance model was established, and glucose levels and gene expression were analyzed through qRT-PCR. The findings indicated that PBMT did not adversely affect cell viability and significantly reduced triglyceride levels and glucose uptake in IR models. Additionally, PBMT altered gene expression related to adipogenesis, suggesting its potential in managing IR and adipocyt

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Insulin ResistanceDiabetes Mellitus, Type 2Low-Level Light TherapyAnimals3T3-L1 CellsMiceAdipocytesGlucoseAdipogenesisCell Survival

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research